Skip to main content

Table 2 Patient characteristics of study population at individual WANETAM study sites

From: The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance

  Burkina Faso The Gambia Ghana Guinea-Bissau Mali Nigeria Ibadan Nigeria Lagos Senegal Togo All study sites
n % n % n % n % n % n % n % n % n % n %
Total 27 (3) 104 (11) 127 (13) 44 (5) 208 (21) 57 (6) 120 (12) 75 (8) 212 (21) 974 (100)
Treatment history New 20 (74) 9 (9) 15 (12) 32 (73) 150 (72) 13 (23) 28 (23) 55 (73) 94 (44) 416 (43)
Retreatment 1 (4) 95 (91) 112 (88) 4 (9) 58 (28) 44 (77) 88 (73) 20 (27) 112 (53) 534 (55)
Unknown 6 (22) 0 (0) 0 (0) 8 (18) 0 (0) 0 (0) 4 (3) 0 (0) 6 (3) 24 (2)
Age 0–14 0 (0) 0 (0) 1 (1) 1 (3) 4 (2) 3 (5) 1 (1) 4 (5) 3 (1) 17 (2)
15–24 3 (14) 31 (30) 16 (13) 10 (26) 50 (24) 6 (10) 16 (14) 12 (16) 27 (13) 171 (18)
25–34 3 (14) 31 (30) 35 (29) 12 (31) 78 (38) 21 (37) 45 (39) 25 (34) 57 (27) 307 (31)
35–44 8 (38) 20 (20) 32 (26) 7 (18) 38 (18) 15 (26) 32 (28) 14 (19) 57 (27) 223 (23)
45–54 3 (14) 10 (10) 26 (21) 6 (15) 21 (10) 8 (14) 12 (10) 7 (9) 42 (20) 135 (14)
55–64 2 (10) 7 (7) 4 (3) 1 (3) 11 (5) 2 (4) 9 (8) 5 (7) 13 (6) 54 (5)
65+ 2 (10) 3 (3) 8 (7) 2 (5) 6 (3) 2 (4) 1 (1) 7 (9) 9 (4) 40 (4)
Unknown 6 2 - 5 - 5 0 0 4 1 4 27 (3)
Sex Female 7 (33) 31 (30) 29 (24) 18 (44) 51 (25) 23 (40) 54 (46) 17 (23) 76 (36) 306 (31)
Male 14 (67) 73 (70) 93 (76) 23 (56) 157 (75) 34 (60) 63 (54) 58 (77) 136 (64) 650 (67)
Unknown 6 0 - 5 - 3 0 0 3 0 1 18 (2)
HIV Negative 0 (0) 56 (54) 25 (20) 0 (0) 172 (83) 42 (74) 46 (38) 15 (20) 115 (54) 471 (48)
Positive 0 (0) 5 (5) 3 (2) 12 (27) 29 (14) 4 (7) 27 (23) 12 (16) 36 (17) 128 (14)
Unknown 27 (100) 43 (41) 99 (78) 32 (73) 7 (3) 11 (19) 47 (39) 48 (64) 61 (29) 375 (38)